Cargando…
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
The development of several treatment options over the last 2 decades has led to a notable improvement in the survival of patients with multiple myeloma. Despite these advances, the disease remains incurable for most patients. Moreover, standard combinations of alkylating agents, immunomodulatory dru...
Autores principales: | Oriol, Albert, Abril, Laura, Torrent, Anna, Ibarra, Gladys, Ribera, Josep-Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170343/ https://www.ncbi.nlm.nih.gov/pubmed/34104374 http://dx.doi.org/10.1177/20406207211019622 |
Ejemplares similares
-
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
por: Delforge, Michel, et al.
Publicado: (2022) -
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
por: Lee, Dae Hyun, et al.
Publicado: (2023) -
Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
por: Connarn, Jamie N., et al.
Publicado: (2023) -
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
por: Logue, Jennifer M., et al.
Publicado: (2022) -
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
por: Jagannath, Sundar, et al.
Publicado: (2021)